{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:03:08Z","timestamp":1762452188181,"version":"build-2065373602"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The genesis of head and neck cancer (HNC) is attributed to the combined influence of genetic and epigenetic irregularities. While surgical resection and radiotherapy remain primary treatment modalities, the effectiveness of current chemotherapeutic options is often hindered by toxicity, resistance, and limited selectivity. Hydroxyurea has long been recognized for its anticancer potential; however, its clinical application is limited by a short half-life, dose-dependent toxicity, and resistance mechanisms. To address these limitations, researchers have focused on developing novel hydroxyurea derivatives with improved pharmacokinetics, target specificity, and multimodal mechanisms of action. In the present study, we report the design and synthesis of two novel 2,2\u2032-bipyridine hydroxamic acid derivatives, including a hydroxyurea analogue aimed at enhancing chemotherapeutic efficacy and safety. Compound\n                    <jats:bold>1A<\/jats:bold>\n                    demonstrated selective cytotoxicity against Cal27 cells (IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u200919.36\u00a0\u03bcM). Mechanistic investigations revealed that\n                    <jats:bold>1A<\/jats:bold>\n                    inhibits cancer cell migration and induces ROS-mediated apoptosis. Additionally,\n                    <jats:bold>1A<\/jats:bold>\n                    exhibited moderate HDAC inhibition, supported by molecular docking and dynamics simulations, which confirmed stable binding to HDAC 2 isoform through Zn\n                    <jats:sup>2<\/jats:sup>\n                    \u207a coordination. These findings place compound\n                    <jats:bold>1A<\/jats:bold>\n                    as a promising lead candidate, integrating epigenetic modulation and direct cytotoxic effects for potential therapeutic application in HNC.\n                  <\/jats:p>","DOI":"10.1007\/s10822-025-00640-1","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:45:23Z","timestamp":1754487923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticancer potential of 2,2\u2032-bipyridine hydroxamic acid derivatives in head and neck cancer therapy"],"prefix":"10.1007","volume":"39","author":[{"given":"Manasa Gangadhar","family":"Shetty","sequence":"first","affiliation":[]},{"given":"Bipasa","family":"Dey","sequence":"additional","affiliation":[]},{"given":"Padmini","family":"Pai","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-9353","authenticated-orcid":false,"given":"Babitha Kampa","family":"Sundara","sequence":"additional","affiliation":[]},{"given":"Kapaettu","family":"Satyamoorthy","sequence":"additional","affiliation":[]},{"given":"Srinivas","family":"Oruganti","sequence":"additional","affiliation":[]},{"given":"Usha Yogendra","family":"Nayak","sequence":"additional","affiliation":[]},{"given":"T.","family":"Ashwini","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"640_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41415-022-5166-x","author":"M Gormley","year":"2008","unstructured":"Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI (2008) Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. https:\/\/doi.org\/10.1038\/s41415-022-5166-x","journal-title":"Br Dent J"},{"key":"640_CR2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22941.1","author":"A Bugshan","year":"2020","unstructured":"Bugshan A, Farooq I (2020) Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F100Research. https:\/\/doi.org\/10.12688\/f1000research.22941.1","journal-title":"F100Research"},{"key":"640_CR3","doi-asserted-by":"publisher","DOI":"10.2174\/1874210601206010126","author":"AK Markopoulos","year":"2012","unstructured":"Markopoulos AK (2012) Current aspects on oral squamous cell carcinoma. Open Dent J. https:\/\/doi.org\/10.2174\/1874210601206010126","journal-title":"Open Dent J"},{"key":"640_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2929","author":"SB Chinn","year":"2015","unstructured":"Chinn SB, Myers JN (2015) Oral cavity carcinoma: current management, controversies, and future directions. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2015.61.2929","journal-title":"J Clin Oncol"},{"key":"640_CR5","unstructured":"National Cancer Institute (2024) Drugs Approved for Head and Neck Cancer, U.S. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/head-neck#drugs-approved-for-head-and-neck-cancer. Accessed 4 June 2025"},{"key":"640_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116211","author":"S Adhikari","year":"2024","unstructured":"Adhikari S, Nath P, Das A, Datta A, Baildya N, Duttaroy AK, Pathak S (2024) A review on metal complexes and its anticancer activities: Recent updates from in vivo studies. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2024.116211","journal-title":"Biomed Pharmacother"},{"key":"640_CR7","volume-title":"Hydroxyurea toxicity","author":"S Jinna","year":"2019","unstructured":"Jinna S, Khandhar PB (2019) Hydroxyurea toxicity. StatPearls Publishing, Treasure Island"},{"key":"640_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2008.00660.x","author":"I Perkovi\u0107","year":"2008","unstructured":"Perkovi\u0107 I, Butula I, Zorc B, Hock K, Paveli\u0107 SK, Paveli\u0107 K, Clercq ED, Balzarini J, Mintas M (2008) Novel lipophilic hydroxyurea derivatives: synthesis, cytostatic and antiviral activity evaluations. Chem Biol Drug. https:\/\/doi.org\/10.1111\/j.1747-0285.2008.00660.x","journal-title":"Chem Biol Drug"},{"key":"640_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms141223654","author":"N \u0160aban","year":"2013","unstructured":"\u0160aban N, Stepani\u0107 V, Vu\u010dini\u0107 S, Horvati\u0107 A, Cindri\u0107 M, Perkovi\u0107 I, Zorc B, Or\u0161oli\u0107 N, Mintas M, Paveli\u0107 K, Paveli\u0107 SK (2013) Antitumor mechanisms of amino acid hydroxyurea derivatives in the metastatic colon cancer model. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms141223654","journal-title":"Int J Mol Sci"},{"key":"640_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102673","author":"G Cheng","year":"2021","unstructured":"Cheng G, Hardy M, Topchyan P, Zander R, Volberding P, Cui W, Kalyanaraman B (2021) Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects. iScience. https:\/\/doi.org\/10.1016\/j.isci.2021.102673","journal-title":"iScience"},{"key":"640_CR11","doi-asserted-by":"publisher","DOI":"10.1021\/jm040869i","author":"N Opa\u010di\u0107","year":"2005","unstructured":"Opa\u010di\u0107 N, Barbari\u0107 M, Zorc B, Cetina M, Nagl A, Frkovi\u0107 D, Kralj M, Paveli\u0107 K, Balzarini J, Andrei G, Snoeck R (2005) The novel L-and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. J Med Chem. https:\/\/doi.org\/10.1021\/jm040869i","journal-title":"J Med Chem"},{"key":"640_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05169-9","author":"M Xu","year":"2024","unstructured":"Xu M, Hou Y, Li N, Yu W, Chen L (2024) Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets. J Transl Med. https:\/\/doi.org\/10.1186\/s12967-024-05169-9","journal-title":"J Transl Med"},{"key":"640_CR13","unstructured":"Chemical Abstracts Service (CAS) (2024). Structure Search\u2014SciFinder\u207f Training and Support, U.S. https:\/\/www.cas.org\/support\/training\/scifinder-n\/structure-search. Accessed 26 March 2024"},{"key":"640_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"},{"key":"640_CR15","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00104","author":"DE Vp","year":"2015","unstructured":"Vp DE, Blundell TL, Ascher DB (2015) pkCSM: predicting small-molecule pharmacokinetic properties using graph-based signatures. J Med Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00104","journal-title":"J Med Chem"},{"key":"640_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(83)90303-4","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4","journal-title":"J Immunol Methods"},{"key":"640_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2017.1421181","author":"WM Eldehna","year":"2018","unstructured":"Eldehna WM, Abo-Ashour MF, Ibrahim HS, Al-Ansary GH, Ghabbour HA, Elaasser MM, Ahmed HY, Safwat NA (2018) Novel [(3-indolylmethylene) hydrazono] indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in vitro biological evaluation. J Enzyme Inhib Med Chem. https:\/\/doi.org\/10.1080\/14756366.2017.1421181","journal-title":"J Enzyme Inhib Med Chem"},{"key":"640_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2018.01.034","author":"H Almahli","year":"2018","unstructured":"Almahli H, Hadchity E, Jaballah MY, Daher R, Ghabbour HA, Kabil MM, Al-Shakliah NS, Eldehna WM (2018) Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer. Bioorg Chem. https:\/\/doi.org\/10.1016\/j.bioorg.2018.01.034","journal-title":"Bioorg Chem"},{"key":"640_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112610","author":"J Qian","year":"2020","unstructured":"Qian J, Xu Z, Meng C, Liu J, Hsu PL, Li Y, Zhu W, Yang Y, Morris-Natschke SL, Lee KH, Zhang Y (2020) Design and synthesis of benzylidenecyclohexenones as TrxR inhibitors displaying high anticancer activity and inducing ROS, apoptosis, and autophagy. Eur J Med Chem. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112610","journal-title":"Eur J Med Chem"},{"key":"640_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104109","author":"F He","year":"2020","unstructured":"He F, Ran Y, Li X, Wang D, Zhang Q, Lv J, Yu C, Qu Y, Zhang X, Xu A, Wei C (2020) Design, synthesis and biological evaluation of dual-function inhibitors targeting NMDAR and HDAC for Alzheimer\u2019s disease. Bioorg Chem. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104109","journal-title":"Bioorg Chem"},{"key":"640_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00894-022-05103-0","author":"P Pai","year":"2022","unstructured":"Pai P, Kumar A, Shetty MG, Kini SG, Krishna MB, Satyamoorthy K, Babitha KS (2022) Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation. J Mol Model. https:\/\/doi.org\/10.1007\/s00894-022-05103-0","journal-title":"J Mol Model"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00640-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00640-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00640-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:56:54Z","timestamp":1762451814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00640-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["640"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00640-1","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"type":"print","value":"0920-654X"},{"type":"electronic","value":"1573-4951"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Further, the authors declare that a patent application (Application Number: 202441019540) has been filed related to the chemical compound discussed in this research. Babitha Kampa Sundara, Kapaettu Satyamoorthy, Manasa Gangadhar Shetty, Padmini Pai, and Srinivas Oruganti are listed as inventors on the patent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"62"}}